Fate Therapeutics (FATE) 25th Annual Needham Virtual Healthcare Conference summary

Key scientific and clinical insights

• CAR T-cell therapy offers a living drug that expands in response to disease burden, providing durable disease control and remission potential in complex, heterogeneous diseases like cancer and lupus.

• The platform uses engineered iPSC-derived CAR T-cells, enabling large-scale, consistent, and cost-effective manufacturing, with a single master cell bank supporting over 10 million doses.

• Off-the-shelf CAR T-cells (FT819) demonstrated safety and efficacy in real-world autoimmune patients, with outpatient, on-demand administration and no grade 3 or higher CRS, ICANS, or GVHD observed.

• Clinical data show rapid and significant reduction in disease activity and fatigue, with improvements in kidney function for lupus nephritis patients.

• Next-generation products (FT836, FT839) incorporate advanced gene edits and multi-targeting strategies, aiming to address solid tumors and complex autoimmune diseases without the need for conditioning.

Pipeline progress and regulatory milestones

• FT819 is in phase I/II for SLE, with plans to initiate a phase II, single-arm, registration-enabling study in lupus nephritis, focusing on complete renal response at six months.

• FT836, targeting MICA/MICB antigens with Sword & Shield technology, showed early clinical activity in solid tumors, including tumor biomarker reduction and lesion shrinkage without conditioning.

• FT839, a multi-edited CAR T-cell for autoimmunity and hematologic malignancies, is completing IND-enabling activities and aims to enter clinical trials in the second half of the year.

• RMAT designation for FT819 enables frequent FDA interactions, supporting accelerated development.

• Upcoming data disclosures are planned at EULAR and ACR, with phase II trial initiation expected between these meetings.

Manufacturing, accessibility, and financial outlook

• The 40,000 sq ft facility can produce up to 50,000 doses per year, supporting both U.S. and international clinical development.

• Off-the-shelf CAR T-cells enable same-day outpatient treatment, improving patient accessibility and reducing hospital stays.

• Repeat dosing every six months is feasible and considered a strength, aligning with current treatment paradigms.

• Enrollment has accelerated as sites and physicians recognize the advantages of the platform, with global expansion underway.

• Over $200 million in cash provides runway through 2027, supported by reduced operating expenses.